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SUMMARY – Pregnancy can alter the natural course of epilepsy and affect pharmacokinetic 
profile of antiepileptic drugs (AEDs) making therapeutic management more demanding. Since there 
is no relevant population-based study in Croatia to date, we conducted this research with the aim to 
observe antiepileptic treatment policy in pregnancy and to determine if the number of AEDs affects 
pregnancy outcomes. The study included all women with epilepsy with singleton pregnancy exposed 
to one or more AEDs divided into two groups (group 1: one AED and group 2: more than one AED 
used). Data were collected retrospectively at the Department of Obstetrics and Gynecology, Zagreb 
University Hospital Centre, Zagreb, Croatia, and included 153 women from January 2010 to Decem-
ber 2018. Primary outcomes included rates of preterm delivery, major fetal malformations, gestational 
hypertension, cesarean section rate, and appearance of seizures during pregnancy. We found higher 
rates of all pregnancy complications examined than in the general population, while comparison of the 
two study groups yielded significant differences. Preterm labor was detected in 30% of deliveries in 
polytherapy group compared to 16.6% in monotherapy group (p=0.03). Gestational hypertension was 
recorded in 20% of women in polytherapy group vs. 4.90% in monotherapy group (p=0.009). There 
was also a high rate of cesarean deliveries in polytherapy group (27.5%). Seizures during pregnancy 
occurred in 48.4% of patients in polytherapy group, which was significantly higher than the rate re-
corded in monotherapy group (p=0.015). In this single-center retrospective study, women with epi-
lepsy using AEDs during pregnancy had a higher rate of gestational hypertension and preterm deliv-
ery than the general population of pregnant women. To the best of our knowledge, this is the first 
study in Croatia observing antiepileptic treatment policy in pregnancy with regards to AED regimen 
and perinatal outcome.
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Introduction
Epilepsy is the most common chronic neurological 
condition characterized by recurrent and transient cen-
tral nervous system dysfunction, affecting 50 million 
people around the world and approximately 40,000 
women in Croatia annually1,2. Approximately 40% of 
women with epilepsy (WWE) are in reproductive age 
with a prevalence of the disease in pregnancy of 0.3%-
0.5%3. Antiepileptic drugs (AEDs) are the most com-
mon teratogenic drugs prescribed to women in repro-
ductive age4,5, with the risk specially increased for val-
proic acid and polytherapy6. Pregnancy can alter the 
natural course of epilepsy and affect pharmacokinetic 
profile of AEDs making therapeutic management 
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more demanding7. According to some population-
based cohort studies, the incidence of epilepsy in preg-
nant women is as high as 0.7%8, with ten-times higher 
maternal mortality in WWE than in those without the 
disorder, most of which is presumably due to sudden 
unexpected death in epilepsy (SUDEP)9. Although the 
use of AED during pregnancy is associated with major 
fetal congenital malformations and long-term cogni-
tive and/or motor impairments, continuous drug treat-
ment is important to control seizures which can have 
deleterious effects on the mother and the fetus1,10.
Since there is no relevant population-based study 
in Croatia to date, we conducted this research with the 
aim to observe antiepileptic treatment policy in preg-
nancy and to determine if the number of AEDs affects 
pregnancy outcomes.
Patients and Methods
The study included all women with epilepsy and 
singleton pregnancy exposed to one or more AEDs, 
who gave birth at the Department of Obstetrics and 
Gynecology, Zagreb University Hospital Centre, Za-
greb, Croatia, from January 2010 to December 2018. 
Data were collected retrospectively by a combination 
of manual and electronic evaluation of clinical charts. 
The study included 153 women and was approved by 
the Department of Obstetrics and Gynecology, Za-
greb University Hospital Centre Ethics Committee.
Maternal epilepsy was not classified according to 
seizure type, epilepsy type and epilepsy syndrome. We 
considered all WWE admitted during the above-
mentioned period and divided them into two groups 
of WWE taking one AED and WWE on multiple 
antiepileptic therapy. Women who had any complica-
tions regarding pre-existing medical condition other 
than epilepsy, fetal structural or chromosomal abnor-
malities and twins were excluded from the study. The 
diagnosis of maternal epilepsy was based on previous 
medical history and medical charts, and was previously 
estimated by a neurologist. Because of the retrospec-
tive nature of the study, there was no consensus about 
diagnostic criteria.
The primary outcomes included rates of preterm 
delivery (delivery before 37 complete weeks of gesta-
tion), major fetal malformations (gestational structural 
abnormality of medical, surgical and aesthetic impor-
tance), gestational hypertension (new onset of hyper-
tension defined as blood pressure ≥140/90 mm Hg 
after 20 weeks of gestation in the absence of protein-
uria), cesarean section rate, and appearance of seizures 
during pregnancy. To note, other gestational hyperten-
sive disorders such as preeclampsia did not occur in 
our cohort, so it was excluded from analysis.
Statistical analysis
The SPSS 17.0 for Windows (SPSS Inc., Chicago, 
IL, U.S.) statistical software was used on data analyses. 
Table 1. Differences in primary outcomes, seizure episodes during pregnancy and valproate 




n % n %
Gestational hypertension No 77 95.1% 32 80.0%
0.009
Yes 4 4.9% 8 20.0%
Preterm labor No 70 86.4% 28 70.0%
0.030
Yes 11 13.6% 12 30.0%
Major fetal malformations No 78 96.3% 40 100.0%
0.218
Yes 3 3.7% 0 0.0%
Elective cesarean section No 73 90.1% 29 72.5%
0.012
Yes 8 9.9% 11 27.5%
Seizure episodes during 
pregnancy
No 51 76.1% 16 51.6%
0.015
Yes 16 23.9% 15 48.4%
Valproate usage No 69 85.2% 23 57.5%
0.001
Yes 12 14.8% 17 42.5%
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Baseline demographic data were expressed as mean ± 
standard deviation and median. Categorical variables 
were compared using the χ2-test. The level of statistical 
significance was set at p<0.05.
Results
During the study period, 28,644 pregnancies were 
recorded in our database. A total of 153 singleton 
pregnant women diagnosed with epilepsy and exposed 
to AED were enrolled, accounting for 0.53% of all de-
liveries. The mean maternal age was 30.17±4.6 years, 
range 17-43 years.
At our hospital, the number of WWE increased 
significantly from 2010 to 2018 (0.22% in 2010 to 
0.65% in 2018). Interestingly, no other comorbidities 
such as depression and other psychiatric disorders 
were diagnosed in WWE during the study.
Study results are shown in Table 1 comparing pri-
mary outcomes between monotherapy and polythera-
py groups. Table 2 illustrates distribution of AED us-
age in our cohort, and even variations between the 
same generic name and their respective combinations 
used. There were 21% of WWE that were not treated 
with AED during pregnancy during the study period 
and they were not enrolled in the study. Only 53% (81 
out of 153 patients) of WWE from our cohort were 
treated with a single AED, whereas four (2.6%) pa-
tients received four AEDs during pregnancy.
Twelve different AEDs were prescribed to WWE 
during the 8-year study period (Table 2). These includ-
ed levetiracetam, lamotrigine, oxcarbazepine, carbam-
azepine, valproate sodium, clonazepam, methylpheno-
barbital, pregabalin, clobazam, zonisamide, topiramate 
and ethosuximide.
Among 81 patients on monotherapy, the most com-
monly used AEDs were levetiracetam (LEV) (n=22; 
27.3%), lamotrigine (LTG) (n=19; 23.5%), oxcarbam-
azepine (n=14; 17.3%), carbamazepine (CBZ) (n=13; 
16.0%) and valproate sodium (VPA) (n=7; 8.6%). Oth-
er drugs used as monotherapy were clonazepam, meth-
ylphenobarbital and ethosuximide (Table 3). There 
were 40 patients on polytherapy, with LEV + VPA as 
the most common combination (17.5%). It is impor-
tant to emphasize that 42.5% of our polytherapy cohort 
used VPA (p=0.001) in combination with LEV, LTG 
or even with older AEDs such as phenytoin (Table 2).
We found a higher rate of all pregnancy complica-
tions examined than in the general population and sig-
nificant differences comparing our two groups (Table 
1). Preterm labor was detected in 30% of deliveries in 
polytherapy group compared to 16.6% in monothera-
py group (p=0.03). Gestational hypertension was diag-
nosed in 20% of women receiving two or more AEDs 
compared to 4.9% in monotherapy group (p=0.009). 
Table 2. Antiepileptic drug usage in study cohort  
with their respective combinations in polytherapy group
Antiepileptic drug Monotherapyn %





Lamal (lamotrigine) 6 7.4
Nirval (levetiracetam) 6 7.4
Phemiton 4 4.9
Lyvam (levetiracetam) 2 2.5
Ethosuximide 1 1.2





Keppra + Depakine 7 17.5
Trileptal + Lamictal 6 15.0
Trileptal + Keppra 4 10.0
Depakine + Arvind 3 7.5
Lamictal + Nirval 3 7.5
Keppra + Topamax 3 7.5
Trileptal + Lamal + Pregabalin + 
Rivotril 2 5.0
Trileptal + Depakine  
+ Lamal + Nirval 2 5.0
Tegretol + Frisium 2 5.0
Phemiton + Depakine 2 5.0
Tegretol + Zonisamid + Topamax 1 2.5
Arvind (lamotrigine)  
+ Lyvam (levetiracetam) 1 2.5
Nirval + Trileptal 1 2.5
Nirval + Trileptal + Phemiton 1 2.5
Lamal + Depakine 1 2.5
Tegretol + Lamal 1 2.5
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There was also a high rate of cesarean deliveries in 
polytherapy group (27.5%). Seizures during pregnancy 
occurred in 48.4% of patients in polytherapy group, 
which was significantly higher compared to mono-
therapy group (p=0.015). The rate of major fetal mal-
formations was higher in monotherapy group (3.7% 
vs. 0%; p=0.218) (Table 1). Two of three major fetal 
malformations occurred in patients treated with VPA 
solely, including neural tube defects in both cases. The 
third fetal major malformation observed was dia-
phragmatic hernia which occurred in a WWE exposed 
to CBZ. Fetal growth, antepartum and postpartum 
hemorrhage, perinatal mortality, Apgar score in 1st and 
5th minute and neonatal intensive care unit (NICU) 
admission did not differ between the two groups.
Discussion
The number of WWE in our hospital increased 
significantly during the 8-year study period. Most of 
the patients were exposed to one AED and the num-
ber of drugs had an impact on pregnancy outcome.
Epilepsy affects approximately 0.3%-0.5% of 
women in childbearing age and it is the most common 
serious neurological condition in pregnancy2. WWE 
were once advised to avoid pregnancy; however, epi-
lepsy is no longer considered a contraindication to 
pregnancy. WWE are nowadays advised to continue 
AED during pregnancy to reduce maternal and fetal 
trauma associated with seizures. The goal of treatment 
is optimal seizure control with minimal fetal exposure 
to AED. Antenatal exposure to AED may be associ-
ated with preterm delivery, intrauterine growth restric-
tion, major fetal congenital malformations, dysmor-
phic syndromes, and defects in neurocognitive devel-
opment11. The management of WWE during preg-
nancy is challenging regarding higher SUDEP and 
mortality rates, risk of seizures10,12,13, perinatal compli-
cations1,14, and teratogenicity of AEDs15.
In this single-center retrospective study, WWE us-
ing AEDs during pregnancy had a higher rate of ges-
tational hypertension, preterm delivery, and major fetal 
malformations than the general population of preg-
nant women. Only half of our patients were on mono-
therapy; in the group on polytherapy, 22% of WWE 
were taking two AEDs, 1.3% were taking three AEDs, 
and 2.6% were treated with four AEDs. Valproate so-
dium still accounted for an unjustifiably high propor-
tion in treatment regimen in both groups. The possible 
explanations are its lower price compared to second-
generation AEDs (such as levetiracetam and lamotrig-
ine), necessity of frequent serum level monitoring of 
second-generation AEDs during pregnancy, which is 
not feasible in Croatia, and inappropriately educated 
primary care physicians regarding second-generation 
AED usage in women of childbearing age.
After determining that almost 80% of our WWE 
were treated with one or more AEDs, it was interest-
ing to detect and compare whether the number of 
AEDs affected perinatal outcome. Large studies con-
firmed teratogenic risks associated with AEDs16-18. In-
trauterine exposure to valproate implies a higher risk 
of major congenital malformations compared to other 
AEDs. Our study found the rate of major fetal malfor-
mations to be higher in monotherapy group and al-
most all major fetal malformations (2 out of 3) oc-
curred in patients treated with VPA solely. Approxi-
mately 43% of our cohort used VPA in their polyther-
apy regimen, but with no increase in the risk of major 
fetal malformations. Current guidelines strongly dis-
courage such approach19-21. Our findings suggest the 
higher rate of major fetal malformations in VPA 
monotherapy group to be dose-related, with no evi-
dence for preconception folate supplementation to re-
duce that risk. All patients treated with VPA mono-
therapy were exposed to >1500 mg dose.
Exposure to AED during pregnancy is associated 
with an increased risk of preterm birth20. Furthermore, 
our study recorded such association and found a signifi-
cantly increased risk of preterm birth in polytherapy 
group compared to monotherapy group (p=0.03). The 
rationale was the increased number of seizures and the 
need for emergency termination of pregnancy (p=0.015).
Considering the significantly increased prevalence 
of AED prescription for women in the reproductive 
age because of conditions other than epilepsy, such as 
mood disorders, chronic pain syndromes and migraine 
headaches, the proportion of pregnant women and fe-
tuses exposed to AEDs may be even higher21. Interest-
ingly, the effect of AED exposure and increased risk of 
preterm birth was also present among women pre-
scribed AED for a psychiatric indication, at least sug-
gesting that the effect may be medication associated22. 
We did not find such comorbidities.
The literature suggests that cesarean delivery is car-
ried out more often in pregnant women with epilepsy 
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than in pregnant women in the general population23. 
Our results did not follow that trend. We found a low 
rate of cesarean section in monotherapy group (9.90%), 
but a significantly higher cesarean section rate in poly-
therapy group (27.5%; p=0.012), suggesting that re-
garding the fear of complications during labor or fear 
that labor might trigger a seizure in polytherapy group 
of patients, obstetricians may have tended to perform 
elective cesarean section as a preferable course of ac-
tion in managing delivery in WWE on polytherapy, 
even in the absence of other indications.
In pregnant WWE, the cause of any increase in 
seizures is not clearly understood and it seems to be 
multifactorial14. Pregnancy is associated with many 
physiological, endocrine and psychological changes, all 
of which may be responsible for the occurrence of sei-
zures. Physiological changes during pregnancy alter 
the pharmacokinetics of AEDs, which may result in 
lower levels and seizure deterioration. Seizure deterio-
ration may be attributed to multiple factors, including 
reduction in AED plasma concentration, changes in 
AED metabolism, sleep deprivation, hormonal chang-
es, and psychological stress. Like Reisinger et al.24, we 
found that WWE in polytherapy group were more 
likely to have seizure deterioration during pregnancy 
than WWE on monotherapy (48.4% vs. 23.9%; 
p=0.015). Almost 50% of women from polytherapy 
group had at least one seizure episode during preg-
nancy, indicating the importance of routine AED se-
rum level assessment, especially for second-generation 
AEDs, such as LEV or LTG. In our cohort, LEV and 
LTG were the most frequently prescribed monothera-
py agents during pregnancy.
Hypertensive pregnancy complications include 
multiple diagnoses with different risks and implications 
for fetal and maternal outcomes. Hypertensive preg-
nancy complications represent a major contributor to 
global maternal mortality25. Most previous studies 
found an increased risk of total hypertensive complica-
tions in WWE. Studies on the effect of specific AEDs 
on pregnant WWE were limited by small sample size, 
selection bias, and lack of detailed information on hy-
pertensive disorders26. Our study showed that most 
WWE did not develop hypertensive complications, but 
that the gestational hypertension rate was significantly 
higher in polytherapy group (20% vs. 4.9%; p=0.009).
How to safely treat pregnant WWE is an impor-
tant question for which there are guidelines, but varia-
tions in practice exist27. This study was conducted to 
better characterize how Croatian physicians address 
this difficult clinical question.
To the best of our knowledge, this is the first study 
in Croatia observing antiepileptic treatment policy in 
pregnancy with regards to AED regimen and perinatal 
outcome. The results demonstrate the first-line drug 
choice to be a consequence of the economic develop-
ment status of the country that plays an important role 
in clinical decision-making process. We found the in 
utero exposure to AED to be associated with an in-
creased risk of major fetal congenital malformations 
although folic acid supplementation at a dose of 5 mg 
was prescribed to all patients. The frequency of serum 
level assessment of AED in our country should be 
more consistent. Maternal anxiety and stress, fluctua-
tion in hormone levels, complicated pharmacokinetic 
changes of AED during pregnancy, and poor compli-
ance may lead to poor control of epilepsy. Inappropri-
ately controlled seizures can cause adverse pregnancy 
outcomes precipitating maternal injuries and intra-
uterine hypoxia.
Our results indicate that pregnancies with epilepsy, 
even in the referral third level center with multidisci-
plinary care and no other risk factors are still signifi-
cantly associated with a higher rate of adverse perina-
tal outcomes.
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Sažetak
UČINAK LIJEČENJA ANTIEPILEPTICIMA U TRUDNOĆI NA PERINATALNE ISHODE  
U REPUBLICI HRVATSKOJ – ISKUSTVO JEDNOG CENTRA
V. Elveđi Gašparović, M. Mikuš, P. Beljan, M. Živković, K. Živković i L. Matak
Trudnoća može izmijeniti prirodni tijek epilepsije i utjecati na farmakokinetiku antiepileptika (AED), što dodatno ote-
žava liječenje. Budući da do danas u Hrvatskoj ne postoji relevantno populacijsko istraživanje, proveli smo istraživanje s 
 ciljem promatranja načina primjene AED-a u trudnoći i utvrđivanja utječe li broj primijenjenih AED-a na ishode trudnoće. 
Istraživanje je obuhvatilo sve žene s epilepsijom i jednoplodnom trudnoćom izložene jednom ili više AED-a podijeljenih u 
dvije skupine (1. skupina: monoterapija i 2. skupina: politerapija). Podaci su prikupljeni retrospektivno u Klinici za ženske 
bolesti i porode KBC Zagreb i pritom su uključene 153 žene od siječnja 2010. do prosinca 2018. godine. Primarni ishodi 
uključivali su stope prijevremenih porođaja, velike fetalne malformacije, gestacijsku hipertenziju, stopu carskog reza i pojavu 
epileptičkih napadaja tijekom trudnoće. Pronašli smo veću stopu svih ispitivanih komplikacija u trudnoći nego u općoj 
 populaciji, dok je usporedba dviju ispitivanih skupina pokazala značajne razlike. Prijevremeni porođaj otkriven je u 30% 
 porođaja u skupini koja je primala politerapiju u usporedbi sa 16,6% u skupini koja je primala monoterapiju (p=0,03). Gesta-
cijska hipertenzija zabilježena je u 20% žena u skupini koja je primala politerapiju u odnosu na 4,90% u skupini koja je pri-
mala monoterapiju (p=0,009). Također je bila visoka stopa porođaja dovršenih carskim rezom u skupini koja je primala 
 politerapiju (27,5%). Napadaji tijekom trudnoće dogodili su se u 48,4% bolesnica u skupini koja je primala politerapiju, što 
je bilo značajno više od stope zabilježene u skupini koja je primala monoterapiju (p=0,015). Zaključno, žene s epilepsijom 
koje su primale AED tijekom trudnoće imale su veću stopu gestacijske hipertenzije i prijevremenih porođaja u usporedbi s 
općom populacijom trudnica. Prema dosadašnjim spoznajama, ovo je prvo istraživanje u Hrvatskoj koje promatra obrasce 
antiepileptičkog liječenja u trudnoći s obzirom na režim AED i perinatalni ishod.
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